{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:17:03Z","timestamp":1791091023629,"version":"4.1.0"},"reference-count":27,"publisher":"Japan Society of Smooth Muscle Research","issue":"5_6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Smooth Muscle Res","J. Smooth Muscle Res."],"published-print":{"date-parts":[[2012]]},"DOI":"10.1540\/jsmr.48.115","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T22:57:23Z","timestamp":1364511443000},"page":"115-124","source":"Crossref","is-referenced-by-count":9,"title":["Effects of ritobegron (KUC-7483), a novel \u03b2<sub>3<\/sub>-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine"],"prefix":"10.1540","volume":"48","author":[{"given":"Itaru","family":"Maruyama","sequence":"first","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Yonekubo","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tatemichi","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyasu","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hoyano","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kusama","sequence":"additional","affiliation":[{"name":"Kissei Pharmaceutical Co., Ltd., Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"435","reference":[{"key":"1","unstructured":"Abrams, P. (2003). Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 62: (5 Suppl 2): 28–37."},{"key":"2","unstructured":"Abrams, P. and Andersson, K.E. (2007). Muscarinic receptor antagonists for overactive bladder. BJU. Int. 100: 987–1006."},{"key":"3","unstructured":"Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A. and Wein, A. (2002). The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21: 167–178."},{"key":"4","unstructured":"Aizawa, N., Igawa, Y., Nishizawa, O. and Wyndaele, J.J. (2010). Effects of CL316,243, a β3<\/sub>-adrenoceptor agonist, and intravesical prostaglandin E2<\/sub> on the primary bladder afferent activity of the rat. Neurourol. Urodyn. 29: 771–776."},{"key":"5","unstructured":"Aizawa. N., Igawa, Y., Nishizawa, O. and Wyndaele, J.J. (2011). Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment. Eur. Urol. 59: 264–271."},{"key":"6","unstructured":"Andersson, K.E. (1999). Advances in the pharmacological control of the bladder. Exp. Physiol. 84: 195–213."},{"key":"7","unstructured":"Barendrecht, M.M., Frazier, E.P., Vrydag, W., Alewijnse, A.E., Peters, S.L. and Michel, M.C. (2009). The effect of bladder outlet obstruction on α1- and β-adrenoceptor expression and function. Neurourol. Urodyn. 28: 349–355."},{"key":"8","unstructured":"Birder, L.A., Nealen, M.L., Kiss, S., de Groat, W.C., Caterina, M.J., Wang, E., Apodaca, G. and Kanai, A.J. (2002). β-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J. Neurosci. 22: 8063–8070."},{"key":"9","unstructured":"Braverman, AS. and Ruggieri, M.R. Sr. (2003). Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3<\/sub> toward M2<\/sub>. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285: 701–708."},{"key":"10","unstructured":"Igawa, Y., Yamazaki, Y., Takeda, H., Akahane, M., Ajisawa, Y., Yoneyama, T. and Nishizawa, O. (1998). Possible β3<\/sub>-adrenoceptor-mediated relaxation of the human detrusor. Acta. Physiol. Scand. 164: 117–118."},{"key":"11","unstructured":"Igawa, Y., Yamazaki, Y., Takeda, H., Hayakawa, K., Akahane, M., Ajisawa, Y., Yoneyama, T., Nishizawa, O. and Andersson, K.E. (1999). Functional and molecular biological evidence for a possible β3<\/sub>-adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. 126: 819–825."},{"key":"12","unstructured":"Jin, LH., Park, CS., Shin, H.Y., Yoon, S.M. and Lee, T. (2011). Dissimilar effects of tolterodine on detrusor overactivity in awake rats with chemical cystitis and partial bladder outlet obstruction. Int. Neurourol. J. 15: 120–126."},{"key":"13","unstructured":"Kaidoh, K., Igawa, Y., Takeda, H., Yamazaki, Y., Akahane, S., Miyata, H., Ajisawa, Y., Nishizawa, O. and Andersson, K.E. (2002). Effects of selective β2<\/sub> and β3<\/sub>-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J. Urol. 168: 1247–1252."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Maruyama, I., Goi, Y., Tatemichi, S., Maruyama, K., Hoyano, Y., Yamazaki, Y. and Kusama, H. (2012b). Bladder selectivity of the novel β3<\/sub>-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat. Naunyn. Schmiedebergs Arch. Pharmacol. 385: 845–852.","DOI":"10.1007\/s00210-012-0755-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Maruyama, I., Tatemichi, S., Goi, Y., Maruyama, K., Hoyano, Y., Yamazaki, Y. and Kusama, H. (2012a). Effects of Ritobegron (KUC-7483), a Novel Selective β3<\/sub>-Adrenoceptor Agonist, on Bladder Function in Cynomolgus Monkey. J. Pharmacol. Exp. Ther. 342: 163–168.","DOI":"10.1124\/jpet.112.191783"},{"key":"16","unstructured":"Nomiya, M. and Yamaguchi, O. (2003). A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J. Urol. 170: 649–653."},{"key":"17","unstructured":"O’Connor, L.T. Jr., Vaughan, E.D. Jr. and Felsen, D. (1997). In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J. Urol. 158: 631–635."},{"key":"18","unstructured":"Otsuka, A., Shinbo, H., Matsumoto, R., Kurita, Y. and Ozono, S. (2008). Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium. Naunyn. Schmiedebergs. Arch. Pharmacol. 377: 473–481."},{"key":"19","unstructured":"Ouslander, JG. (2004). Management of overactive bladder. N. Engl. J. Med. 350: 786–799."},{"key":"20","unstructured":"Park, M.G., Park, H.S., Lee, J.G. and Kim, H.J. (2010). Changes in Awake Cystometry and Expression of Bladder β-adrenoceptors after Partial Bladder Outlet Obstruction in Male Rats. Int. Neurourol. J. 14: 157–163."},{"key":"21","unstructured":"Takeda, H., Yamazaki, Y., Igawa, Y., Kaidoh, K., Akahane, S., Miyata, H., Nishizawa, O., Akahane, M. and Andersson, K.E. (2002). Effects of β3<\/sub>-adrenoceptor stimulation on prostaglandin E2<\/sub>-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol. Urodyn. 21: 558–565."},{"key":"22","unstructured":"Tyagi, P., Thomas, C.A., Yoshimura, N. and Chancellor, M.B. (2009). Investigations into the presence of functional β1<\/sub>, β2<\/sub> and β3<\/sub>-adrenoceptors in urothelium and detrusor of human bladder. Int. Braz. J. Urol. 35: 76–83."},{"key":"23","unstructured":"Woods, M., Carson, N., Norton, N.W., Sheldon, J.H. and Argentieri, T.M. (2001). Efficacy of the β3<\/sub>-adrenergic receptor agonist CL316,243 on experimental bladder hyperreflexia and detrusor instability in the rat. J. Urol. 166: 1142–1147."},{"key":"24","unstructured":"Wyndaele, J-J., van Meel, T.D. and de Wachter, S. (2004). Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J. Urol. 172: 1915–1918."},{"key":"25","unstructured":"Yamaguchi, O. (2002). β3<\/sub>-adrenoceptors in human detrusor muscle. Urology. 59: 25–29."},{"key":"26","unstructured":"Yamaguchi, O. and Chapple. C.R. (2007). β3<\/sub>-adrenoceptors in urinary bladder. Neurourol. Urodyn. 26: 752–756."},{"key":"27","unstructured":"Yamazaki, Y., Takeda, H., Akahane, M., Igawa, Y., Nishizawa, O. and Ajisawa, Y. (1998). Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth muscle. Br. J. Pharmacol. 124: 593–599."}],"container-title":["Journal of Smooth Muscle Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsmr\/48\/5_6\/48_115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T20:01:27Z","timestamp":1619035287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsmr\/48\/5_6\/48_115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":27,"journal-issue":{"issue":"5_6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1540\/jsmr.48.115","relation":{},"ISSN":["0916-8737","1884-8796"],"issn-type":[{"value":"0916-8737","type":"print"},{"value":"1884-8796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}